{
  "story_id": "6591ff75b3ae0374bb5523a7759cad2d",
  "desk": "drm3",
  "revision": 1,
  "published_at": "2026-09-04T03:03:11.000Z",
  "content_hash": "fb35a554963416663121bfdda0e7bac61e816a5ee142917ea2067088b38e5403",
  "hash_basis": "sha256 over `headline\\ndek\\nprose`, plus `\\n` + the canonical citations JSON when any source is placed, plus `\\n#blog` for blogs",
  "basis": {
    "headline": "New Zealand Approves Pharmaceutical-Grade MDMA for PTSD Treatment",
    "dek": "New Zealand regulators have approved pharmaceutical-grade MDMA combined with psychotherapy for treating severe PTSD.",
    "prose": "New Zealand health regulator Medsafe approved on Friday the prescription of pharmaceutical-grade MDMA for treating severe post-traumatic stress disorder (PTSD). [^1]\n\nTwo psychiatrists in New Zealand obtained authorization on Friday to prescribe pharmaceutical-grade MDMA to individuals suffering from severe post-traumatic stress disorder (PTSD). [^2]\n\nNew Zealand becomes the second country in the world to approve MDMA for PTSD treatment, following Australia which approved the use in 2023. [^3]\n\nThe approved treatment protocol involves administering MDMA in combination with psychotherapy within a controlled clinical environment under the supervision of an authorized psychiatrist. [^4]\n\nVice-Premier David Seymour stated that New Zealand is determined to make innovative treatments more accessible and described PTSD as a condition that destroys lives and is difficult to treat. [^5]\n\nThe Ministry of Health indicated that MDMA-assisted treatment will be combined with psychotherapy and that patients, who must be over 18, will not be given drugs to take home. [^6]\n\nIn the United States, clinical trials are ongoing after the Federal Drug Administration (FDA) rejected the legalization of medicinal MDMA use in 2024, citing insufficient evidence of safety and efficacy. [^7]",
    "cited": "[{\"statement\":\"New Zealand health regulator Medsafe approved on Friday the prescription of pharmaceutical-grade MDMA for treating severe post-traumatic stress disorder (PTSD).\",\"source\":\"Berlingske\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-04T02:15:44.000Z\",\"publisher_count\":1,\"sources\":[\"Berlingske\"]},{\"statement\":\"Two psychiatrists in New Zealand obtained authorization on Friday to prescribe pharmaceutical-grade MDMA to individuals suffering from severe post-traumatic stress disorder (PTSD).\",\"source\":\"El Economista\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-04T03:03:11.000Z\",\"publisher_count\":1,\"sources\":[\"El Economista\"]},{\"statement\":\"New Zealand becomes the second country in the world to approve MDMA for PTSD treatment, following Australia which approved the use in 2023.\",\"source\":\"Berlingske\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-04T02:15:44.000Z\",\"publisher_count\":1,\"sources\":[\"Berlingske\"]},{\"statement\":\"The approved treatment protocol involves administering MDMA in combination with psychotherapy within a controlled clinical environment under the supervision of an authorized psychiatrist.\",\"source\":\"Berlingske\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-04T02:15:44.000Z\",\"publisher_count\":1,\"sources\":[\"Berlingske\"]},{\"statement\":\"Vice-Premier David Seymour stated that New Zealand is determined to make innovative treatments more accessible and described PTSD as a condition that destroys lives and is difficult to treat.\",\"source\":\"Berlingske\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-04T02:15:44.000Z\",\"publisher_count\":1,\"sources\":[\"Berlingske\"]},{\"statement\":\"The Ministry of Health indicated that MDMA-assisted treatment will be combined with psychotherapy and that patients, who must be over 18, will not be given drugs to take home.\",\"source\":\"El Economista\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-04T03:03:11.000Z\",\"publisher_count\":1,\"sources\":[\"El Economista\"]},{\"statement\":\"In the United States, clinical trials are ongoing after the Federal Drug Administration (FDA) rejected the legalization of medicinal MDMA use in 2024, citing insufficient evidence of safety and efficacy.\",\"source\":\"El Economista\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-04T03:03:11.000Z\",\"publisher_count\":1,\"sources\":[\"El Economista\"]}]",
    "kind": "news"
  },
  "receipt_verify": "Ed25519 over the dot-joined string `slice_hash.cursor_from.cursor_to.view.view_version.row_count`; public_key and sig are base64url of the raw 32-byte key / 64-byte signature",
  "receipt": null,
  "receipt_note": "this revision predates receipt-keeping (before v0.37.0); the filed row lives in the record",
  "generation_chain": {
    "wire": {
      "stream": "fountain_news",
      "story_id": "d1cb65f0cae063a7f9bbe8ba3e28c834",
      "thread_id": "bf2de6cdd73495e07cd44c7c06703ac1",
      "thread_label": "Medsafe",
      "novelty": "UPDATE",
      "content_hash": "5ef861ff843eb38c007eb2ad5b6a0c192e2322ed5804ccba99e01a80151ed3d6",
      "last_published_at": "2026-09-04T03:03:11.000Z",
      "read_receipt": {
        "slice_hash": "9aaaeba2800b536e54f2564bd2dee1e9d7fb8addbfcc357abd16c2411c3e1fda",
        "cursor_from": "eyJ0cyI6IjIwMjYtMDktMDRUMDI6NTk6MDYuMDAwMDAwWiIsImlkIjoiMGUxMjEzNGQ5MjliNjdmNWE0Yjc5Mzg5ZmJlNjg3NzIiLCJ2IjoiMSJ9",
        "cursor_to": "eyJ0cyI6IjIwMjYtMDktMDRUMDQ6MDA6MDAuMDAwMDAwWiIsImlkIjoiMjdkNmMxNTc0ZTI3OThkMTZkYWY2ZDc4YWYzODMzYzYiLCJ2IjoiMSJ9",
        "view": "v_fountain_news",
        "view_version": "1",
        "row_count": 100,
        "window_days": 3,
        "bytes_scanned": 12166856,
        "credits": 8,
        "price_per_100_rows": 8,
        "sig": "iiAnVxxS5ymxgbGuE-M0jIU3u4Wd-Uxyc-zkk32g9kjb5xHnbr6F7whvMUAlnW1HAy9wDXYvQCe6wnJv0POHCQ",
        "public_key": "bMUigy8O0jOnBxQ4Sc-5lwhIZ8LQVAhxMbR7qESVuUE",
        "signer_path": "lakehouse/data-extract/v1",
        "alg": "Ed25519",
        "signed": true
      }
    },
    "written_at": "2026-09-04T07:01:03.766Z"
  },
  "cited_facts": [
    {
      "statement": "New Zealand health regulator Medsafe approved on Friday the prescription of pharmaceutical-grade MDMA for treating severe post-traumatic stress disorder (PTSD).",
      "source": "Berlingske",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-04T02:15:44.000Z",
      "publisher_count": 1,
      "sources": [
        "Berlingske"
      ]
    },
    {
      "statement": "Two psychiatrists in New Zealand obtained authorization on Friday to prescribe pharmaceutical-grade MDMA to individuals suffering from severe post-traumatic stress disorder (PTSD).",
      "source": "El Economista",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-04T03:03:11.000Z",
      "publisher_count": 1,
      "sources": [
        "El Economista"
      ]
    },
    {
      "statement": "New Zealand becomes the second country in the world to approve MDMA for PTSD treatment, following Australia which approved the use in 2023.",
      "source": "Berlingske",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-04T02:15:44.000Z",
      "publisher_count": 1,
      "sources": [
        "Berlingske"
      ]
    },
    {
      "statement": "The approved treatment protocol involves administering MDMA in combination with psychotherapy within a controlled clinical environment under the supervision of an authorized psychiatrist.",
      "source": "Berlingske",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-04T02:15:44.000Z",
      "publisher_count": 1,
      "sources": [
        "Berlingske"
      ]
    },
    {
      "statement": "Vice-Premier David Seymour stated that New Zealand is determined to make innovative treatments more accessible and described PTSD as a condition that destroys lives and is difficult to treat.",
      "source": "Berlingske",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-04T02:15:44.000Z",
      "publisher_count": 1,
      "sources": [
        "Berlingske"
      ]
    },
    {
      "statement": "The Ministry of Health indicated that MDMA-assisted treatment will be combined with psychotherapy and that patients, who must be over 18, will not be given drugs to take home.",
      "source": "El Economista",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-04T03:03:11.000Z",
      "publisher_count": 1,
      "sources": [
        "El Economista"
      ]
    },
    {
      "statement": "In the United States, clinical trials are ongoing after the Federal Drug Administration (FDA) rejected the legalization of medicinal MDMA use in 2024, citing insufficient evidence of safety and efficacy.",
      "source": "El Economista",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-04T03:03:11.000Z",
      "publisher_count": 1,
      "sources": [
        "El Economista"
      ]
    }
  ],
  "note": "A signature proves who filed this and that it has not changed since. It never makes a claim true."
}